FDA has granted accelerated approval to Tecentriq (atezolizumab) plus chemotherapy (Abraxane [nab-paclitaxel]) for the treatment of adults with unresectable locally advanced or metastatic triple-negative breast cancer in people whose tumors express PD-L1, as determined by an FDA-approved test.
The NCI Human Tumor Atlas Network (HTAN) has published a cluster of papers intended to advance the framework of spatial omics, the science of profiling morphological and molecular features of human cancers in two and three dimensions.
